ArticleRadiation oncology (London, England)2025
Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Early Outcomes of Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Retrospective Analysis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Development and validation of a biochemical recurrence risk assessment model for prostate cancer based on TCGA database.Translational andrology and urology · 2026Article
- A cone-beam computed tomography based workflow for online adaptive ultra-hypofractionated radiotherapy of prostate cancer.Physics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExternal beam radiotherapy (EBRT) is a standard treatment for localized prostate cancer, with recent advancements favoring a reduced number of treatment sessions. Stereotactic body radiotherapy (SBRT) is a form of radiotherapy that delivers higher doses per fraction, typically in five or fewer sessions. This retrospective study aims to evaluate the implementation of the PACE-SBRT protocol for localized prostate cancer at our center by assessing the incidence and severity of toxicity, as well as biochemical relapse-free survival.
methodsWe conducted a retrospective analysis of patients with localized prostate cancer treated with SBRT at the Iridium Network in Antwerp, Belgium, who were treated between January 1, 2020, and December 31, 2022. Data were extracted from electronic medical records and included descriptive information on patient outcomes. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Acute toxicity was defined as events occurring within 90 days post-SBRT, whereas late toxicity was evaluated at 6 months, 1 year, 2 years, and 3 years post treatment. Biochemical recurrence was defined via the Phoenix criteria, as a rise in PSA levels of 2 ng/mL or more above the post treatment nadir.
resultsA total of 267 patients met the eligibility criteria for this study. In total, 9% of patients were low risk, 51% were intermediate risk, and 40% were high risk. The cumulative incidence of Grade 2 or higher GU toxicity was 27%, and for GI toxicity, it was 2%. At 24 months, 11.5% (20/175) of patients experienced CTCAE grade 2 or higher GU toxicity, and 1.7% (3/175) experienced grade 2 or higher GI toxicity. Biochemical relapse occurred in 1.5% (4/267) of patients, leading to a 2-year biochemical relapse-free survival rate of 98.5%.
conclusionSBRT for localized prostate cancer has favorable oncological outcomes with a low incidence of Grade 2 or higher toxicity. The results of this study are consistent with findings from prospective trials, suggesting that SBRT is an effective treatment modality. Trial registration Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.